CMS’ “Potential” NCD List Gets Stakeholder Support, But Questions Remain
This article was originally published in The Gray Sheet
Executive Summary
The device industry and other Medicare stakeholders are generally supportive of CMS' recent move to publicize topics it is considering for future national coverage determinations, though some worry that the agency will use the process to limit patient access to technologies
You may also be interested in...
Data Lacking On Proton Therapy Vs. Traditional Radiation For Cancer - AHRQ
Particle beam radiation - also known as proton therapy - is a "promising" cancer treatment, but potential advantages over alternative radiation therapies remain unproven due to a lack of long-term comparative studies, according to a Sept. 14 Agency for Healthcare Research and Quality technical brief
Data Lacking On Proton Therapy Vs. Traditional Radiation For Cancer - AHRQ
Particle beam radiation - also known as proton therapy - is a "promising" cancer treatment, but potential advantages over alternative radiation therapies remain unproven due to a lack of long-term comparative studies, according to a Sept. 14 Agency for Healthcare Research and Quality technical brief
Debate Stirs Over Medicare Coverage For Proton Therapy In Prostate Cancer
A private insurer is calling for CMS to issue a national non-coverage decision for proton therapy in treating prostate cancer, claiming Medicare payments will encourage rapid spread of the costly technology before there is enough clinical evidence to deem the treatment reasonable and necessary